Abstract:A group of post-natal neurodevelopmental disorders collectively referred to as MeCP2 disorders are caused by aberrations in the gene encoding methyl-CpG-binding protein 2 (MECP2). Loss of MeCP2 function causes Rett syndrome (RTT), whereas increased copy number of the gene causes MECP2 duplication or triplication syndromes. MeCP2 acts as a transcriptional repressor, however the gene expression changes observed in the hypothalamus of MeCP2 disorder mouse models suggest that MeCP2 can also upregulate gene expression, given that the majority of genes are downregulated upon loss of MeCP2 and upregulated in its presence. To determine if this dual role of MeCP2 extends beyond the hypothalamus, we studied gene expression patterns in the cerebellum of Mecp2-null and MECP2-Tg mice, modeling RTT and MECP2 duplication syndrome, respectively. We found that abnormal MeCP2 dosage causes alterations in the expression of hundreds of genes in the cerebellum. The majority of genes were upregulated in MECP2-Tg mice and downregulated in Mecp2-null mice, consistent with a role for MeCP2 as a modulator that can both increase and decrease gene expression. Interestingly, many of the genes altered in the cerebellum, particularly those increased by the presence of MeCP2 and decreased in its absence, were similarly altered in the hypothalamus. Our data suggest that either gain or loss of MeCP2 results in gene expression changes in multiple brain regions and that some of these changes are global. Further delineation of the expression pattern of MeCP2 target genes throughout the brain might identify subsets of genes that are more amenable to manipulation, and can thus be used to modulate some of the disease phenotypes.

Expression of Phospho-MeCP2s in the Developing Rat Brain and Function of Postnatal MeCP2 in Cerebellar Neural Cell Development

Downregulation of CNPase in a MeCP2 Deficient Mouse Model of Rett Syndrome.

Selective Preservation of Cholinergic Mecp2 Rescues Specific Rett-Syndrome-Like Phenotypes in Mecp2(Stop) Mice

MeCP2 Deficiency in Neuroglia: New Progress in the Pathogenesis of Rett Syndrome.

Research Progress of Rett Syndrome Causing Gene MECP2-The Structure, Function and Modulation of MECP2

MeCP2: Multifaceted Roles in Gene Regulation and Neural Development

Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus

The methyl-CpG-binding domain (MBD) is crucial for MeCP2's dysfunction-induced defects in adult newborn neurons.

Loss of MeCP2 in immature neurons leads to impaired network integration.

[Expression of Mythl-Cpg-binding Protein-2 Gene in Developing Rat Brain].

MeCP2, a Key Contributor to Neurological Disease, Activates and Represses Transcription

Regulation Mechanism and Research Progress of MeCP2 in Rett Syndrome

Mecp2 Regulates The Timing Of Critical Period Plasticity That Shapes Functional Connectivity In Primary Visual Cortex

Manipulations of MeCP2 in Glutamatergic Neurons Highlight Their Contributions to Rett and Other Neurological Disorders.

Regulation of mRNA splicing by MeCP2 via epigenetic modifications in the brain

Loss of O-GlcNAcylation on MeCP2 at Threonine 203 Leads to Neurodevelopmental Disorders

Differential dynamics specify MeCP2 function at nucleosomes and methylated DNA

MeCP2 Deficiency Impairs Motor Cortical Circuit Flexibility Associated with Motor Learning

Testing the PEST hypothesis using relevant Rett mutations in MeCP2 E1 and E2 isoforms

Graded and pan-neural disease phenotypes of Rett Syndrome linked with dosage of functional MeCP2

MeCP2 links heterochromatin condensates and neurodevelopmental disease